CMV DNA polymerase Inhibitors
1 drugsAbout CMV DNA polymerase
CMV DNA polymerase is essential for cytomegalovirus (CMV) replication, a virus causing serious issues in immunocompromised individuals. Inhibiting this enzyme halts viral replication, reducing viral load and alleviating disease symptoms.
CMV DNA polymerase is a viable antiviral target, though there is currently no genetic evidence linking variations in the polymerase gene to disease susceptibility.
One FDA-approved drug, cidofovir, targets CMV DNA polymerase as a small molecule. AVET LIFESCIENCES markets cidofovir for two indications since 2012.
Top CMV DNA polymerase Drugs
AVET LIFESCIENCES is the only company with an approved drug targeting CMV DNA polymerase.
Low competition presents an opportunity for new entrants, but also indicates potential market challenges.
CMV DNA polymerase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CMV DNA polymerase, using small molecule modality.
Explore novel modalities like antibodies or gene therapies to differentiate from existing treatments.
CMV DNA polymerase Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CMV DNA polymerase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 1 | 1 | 67% |
| Phase 3 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved CMV DNA polymerase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CMV DNA polymerase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
CMV DNA polymerase Drug Approval Timeline (2012 - 2012)
The first and only drug, cidofovir, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new CMV DNA polymerase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CMV DNA polymerase. A trial counts if an approved drug acting on CMV DNA polymerase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.